The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
REGULATORY
PMDA to Specify Target Overall Review Period for Regenerative Medicine Products: FY2019-2023 Plan
The Pharmaceuticals and Medical Devices Agency (PMDA) on January 16 presented a draft of its fourth midterm plan for FY2019-2023, newly setting the target total review time for regenerative medicine products. The agency aims to achieve a total review time…
To read the full story
Related Article
- PMDA Eyeing Staffer Increase of Around 150 over Next 5 Years, Official Suggests
January 29, 2019
- PMDA to Raise Its Service Fees, Up 28% for New Drug Reviews; MHLW Invites Public Opinions
January 17, 2019
- PMDA to Raise Fees and Expand Workforce to Boost Review and Safety Measures, GMP Inspection
January 15, 2019
REGULATORY
- Opposition Parties Submit Bill to Scrap Off-Year Drug Price Revisions
December 23, 2024
- Health Ministry Panel Endorses RX-to-OTC Switches of 3 PPIs
December 23, 2024
- Off-Year Price Revision to Hit 53% of Listed Drugs in 2025, Down from 69%
December 23, 2024
- Three Ministers Agree on Off-Year Drug Price Revision in FY2025
December 20, 2024
- Japan Set to Settle Off-Year Debate with “x1.0” Threshold for PMP Meds/Generics, “x0.5” for LLPs
December 20, 2024
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…